Last reviewed · How we verify
NCT03680586
Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma
EARLY_PHASE1 trial testing Radiation Therapy in Gastric Mucosa-Associated Lymphoid Tissue Lymphoma in 25 participants. Participants enrolled and being followed up; not accepting new ones.
30 April 2028
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 4 February 2019 |
| Primary completion | 30 April 2028 |
| Estimated completion | 30 April 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Radiation Therapy — full drug profile →
Conditions studied
- Gastric Mucosa-Associated Lymphoid Tissue Lymphoma — all drugs for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies how well ultra low-dose radiation therapy works in treating patients with stage I-IV stomach mucosa-associated lymphoid tissue (MALT) lymphoma. Ultra low-dose radiation therapy may be able to kill tumor cells and shrink tumors while having fewer side effects in patients with MALT lymphoma.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial.
Gunther JR, Xu J, Bhutani MS, Strati P, et al · · 2024 · cited 19× · PMID 38843856 · DOI 10.1016/s2352-3026(24)00133-9 -
Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas.
Cerrato M, Orlandi E, Vella A, Bartoncini S, et al · · 2021 · cited 11× · PMID 34111959 · DOI 10.1259/bjr.20210012 -
A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma.
Fang P, Gunther JR, Pinnix CC, Dong W, et al · · 2021 · cited 11× · PMID 33309978 · DOI 10.1016/j.ijrobp.2020.11.070 -
Risk of Diabetes Mellitus after Radiotherapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.
Lee J, Yoon HI, Kim J, Cho J, et al · · 2022 · cited 3× · PMID 36077647 · DOI 10.3390/cancers14174110 -
Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma.
Rolf D, Reinartz G, Rehn S, Kittel C, et al · · 2022 · cited 3× · PMID 35205623 · DOI 10.3390/cancers14040873 -
Long-term Clinical Efficacy of Radiotherapy for Patients with Stage I-II Gastric Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A Retrospective Multi-institutional Study.
Jeong JU, Lee HC, Song JH, Eom KY, et al · · 2025 · cited 2× · PMID 39363583 · DOI 10.4143/crt.2024.651 -
Two rare cases of bronchus-associated lymphoid tissue lymphoma successfully treated with rituximab-bendamustine.
Panitz N, Gerhardt K, Becker C, Schleife H, et al · · 2021 · cited 2× · PMID 34401153 · DOI 10.1002/ccr3.4557
Verify or expand the search:
- PubMed search for NCT03680586
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radiation Therapy
Trials testing the same drug.
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07195734 — Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT07466316 — A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Ove · Phase 3 · not yet recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03680586 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03680586.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing